ICI/TKI Combo Maintains Survival Benefit in Advanced RCC
SAN FRANCISCO — First-line nivolumab (Opdivo) plus cabozantinib (Cabometyx) continued to demonstrate clinically meaningful survival benefits in advanced renal cell carcinoma (RCC). An update of the CheckMate 9ER trial, which compared the immune checkpoint inhibitor/tyrosine kinase inhibitor (TKI) doublet with the TKI sunitinib (Sutent), showed that after 44 months of median follow-up, median progression-free survival […]
Triplet in First-Line Kidney Cancer Thwarts Disease Progression
PARIS — Adding the tyrosine kinase inhibitor (TKI) cabozantinib (Cabometyx) to dual immune checkpoint inhibition improved progression-free survival (PFS) in patients with advanced renal cell carcinoma (RCC), the phase III COSMIC-313 trial found. Among 550 patients with untreated intermediate- or poor-risk disease, those treated with the triplet therapy had a median PFS that was not […]